托珠单抗联合标准治疗对比标准治疗用于印度中重度COVID-19相关细胞因子释放综合征患者:COVINTOC开放标签多中心随机对照3期试验
COVINTOC试验在印度12家医院纳入180例中重度COVID-19住院患者,随机接受托珠单抗6 mg/kg联合标准治疗或仅标准治疗。常规使用托珠单抗不支持,但事后分析提示对重症患者可能有效。
要点
- 托珠单抗未显著降低中重度COVID-19患者第14天疾病进展风险。
- 两组不良事件和严重不良事件发生率相似,最常见为急性呼吸窘迫综合征。
- 事后证据提示托珠单抗对重症COVID-19可能有效,需进一步研究。
核心结论
- 常规使用托珠单抗治疗中重度COVID-19住院患者不被支持。
- 事后证据提示托珠单抗对重症COVID-19可能仍有效,需未来研究进一步验证。
研究设计与样本
- COVINTOC为开放标签、多中心、随机对照3期试验,在印度12家公立和私立医院进行。
- 纳入180例≥18岁中重度COVID-19住院患者(印度卫生部评级,SARS-CoV-2 PCR阳性),1:1区组随机分配至托珠单抗6 mg/kg联合标准治疗组(n=90)或标准治疗组(n=90)。
- 主要终点为第14天COVID-19进展(中度转重度或重度转死亡),在改良意向治疗人群(至少一次基线后主要终点评估)中分析;安全性分析纳入所有随机患者。
主要发现
- 不良事件:托珠单抗组33/91(36%) vs 标准治疗组22/89(25%);严重不良事件分别为18/91(20%)和15/89(17%)。
- 最常见不良事件为急性呼吸窘迫综合征,两组各7例(8%);3级不良事件分别为2/91(2%)和5/89(6%),无4级不良事件。
- 死亡:托珠单抗组13/91(14%) vs 标准治疗组15/89(17%)。
临床怎么用
- 不推荐中重度COVID-19住院患者常规使用托珠单抗。
- 重症COVID-19患者使用托珠单抗需权衡获益风险,并考虑进一步研究背景。
局限性
- 开放标签设计可能引入偏倚。
- 样本量较小(180例),事后分析证据需谨慎解读。
- 研究仅在印度进行,结果外推需考虑人群差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Global randomised controlled trials of the anti-IL-6 receptor antibody tocilizumab in patients admitted to hospital with COVID-19 have shown conflicting results but potential decreases in time to discharge and burden on intensive care. Tocilizumab reduced progression to mechanical ventilation and death in a trial population enriched for racial and ethnic minorities. We aimed to investigate whether tocilizumab treatment could prevent COVID-19 progression in the first multicentre randomised controlled trial of tocilizumab done entirely in a lower-middle-income country. METHODS: COVINTOC is an open-label, multicentre, randomised, controlled, phase 3 trial done at 12 public and private hospitals across India. Adults (aged ≥18 years) admitted to hospital with moderate to severe COVID-19 (Indian Ministry of Health grading) confirmed by positive SARS-CoV-2 PCR result were randomly assigned (1:1 block randomisation) to receive tocilizumab 6 mg/kg plus standard care (the tocilizumab group) or standard care alone (the standard care group). The primary endpoint was progression of COVID-19 (from moderate to severe or from severe to death) up to day 14 in the modified intention-to-treat population of all participants who had at least one post-baseline assessment for the primary endpoint. Safety was assessed in all randomly assigned patients. The trial is completed and registered with the Clinical Trials Registry India (CTRI/2020/05/025369). FINDINGS: 180 patients were recruited between May 30, 2020, and Aug 31, 2020, and randomly assigned to the tocilizumab group (n=90) or the standard care group (n=90). One patient randomly assigned to the standard care group inadvertently received tocilizumab at baseline and was included in the tocilizumab group for all analyses. One patient randomly assigned to the standard care group withdrew consent after the baseline visit and did not receive any study medication and was not included in the modified intention-to-treat population but was still included in safety analyses. 75 (82%) of 91 in the tocilizumab group and 68 (76%) of 89 in the standard care group completed 28 days of follow-up. Progression of COVID-19 up to day 14 occurred in eight (9%) of 91 patients in the tocilizumab group and 11 (13%) of 88 in the standard care group (difference -3·71 [95% CI -18·23 to 11·19]; p=0·42). 33 (36%) of 91 patients in the tocilizumab group and 22 (25%) of 89 patients in the standard care group had adverse events; 18 (20%) and 15 (17%) had serious adverse events. The most common adverse event was acute respiratory distress syndrome, reported in seven (8%) patients in each group. Grade 3 adverse events were reported in two (2%) patients in the tocilizumab group and five (6%) patients in the standard care group. There were no grade 4 adverse events. Serious adverse events were reported in 18 (20%) patients in the tocilizumab group and 15 (17%) in the standard care group; 13 (14%) and 15 (17%) patients died during the study. INTERPRETATION: Routine use of tocilizumab in patients admitted to hospital with moderate to severe COVID-19 is not supported. However, post-hoc evidence from this study suggests tocilizumab might still be effective in patients with severe COVID-19 and so should be investigated further in future studies. FUNDING: Medanta Institute of Education and Research, Roche India, Cipla India, and Action COVID-19 India.
引用
- Soin AS, Kumar K, Choudhary NS, et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respir Med. 2021. PMID: 33676589. doi:10.1016/S2213-2600(21)00081-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。